DÄ internationalArchiveReferences

Review article

Novel Therapies in Advanced Renal Cell Carcinoma

Dtsch Arztebl Int 2008; 105(13): 232-7. DOI: 10.3238/arztebl.2008.0232

Ivanyi, P; Winkler, T; Ganser, A; Reuter, C; Grünwald, V

1. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005; 23: 2477–90. MEDLINE
2. Brugarolas J: Renal-cell carcinoma – molecular pathways and therapies. N Engl J Med 2007; 2: 185–7. MEDLINE
3. Müller-Tidow C, Krug U, Brunnberg U, Berdel WE, Serve H: Tyrosinkinasen als Ziele neuer onkologischer Therapien. Dtsch Arztebl 2007; 19: 1312–9. VOLLTEXT
4. Motzer RJ, Hutson TE, Tomczak P et al.: Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma. N Engl J Med 2007; 2: 115–24. MEDLINE
5. Escudier B, Eisen T, Stadler WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 2: 125–34. MEDLINE
6. Verheul HM, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 6: 475–85. MEDLINE
7. Gore M, Porta C, Oudard S et al.: Sunitinib in metastatic renal cell carcinoma (mrcc): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol ASCO Annual Meeting Proceedings 2007; 25: 5010.
8. Drabkin HA, Figlin RA, Stadler WM et al.: The advanced renal cell carcinoma sorafenib (arccs) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (bev) treatment. J Clin Oncol ASCO Annual Meeting Proceedings 2007; 25: 5041–7.
9. Ratain MJ, Eisen T, Stadler WM et al.: Phase-II-placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 16: 2505–12. MEDLINE
10. Faivre S, Delbaldo C, Vera K et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 1: 25–35. MEDLINE
11. Senior K: Fatigue with sunitinib-induced hypothyroidism. Lancet Oncol 2007; 2: 101. MEDLINE
12. Wolter P, Dumez H, Schöffski P: Sunitinib and hypothyroidism. N Engl J Med 2007; 15: 1580. MEDLINE
13. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW: Hand-foot-syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 36: 5786–8. MEDLINE
14. Strumberg D, Clark JW, Awada A et al.: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 4: 426–37. MEDLINE
15. Veronese ML, Mosenkis A, Flaherty KT et al.: Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 9: 1363–9. MEDLINE
16. Desai J, Yassa L, Marqusee E et al.: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 9: 660–4. MEDLINE
17. Wong E, Rosen LS, Mulay M et al.: Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007; 4: 351–5. MEDLINE
18. Rini BI, Tamaskar I, Shaheen P et al.: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 1: 81–3. MEDLINE
19. Tamaskar IR, Unnithan J, Garcia JA, et al.: Thyroid function test (TFT) abnormalities in patients with metastatic renal cell carcinoma (RCC) treated with sorafenib. J Clin Oncol ASCO Annual Meeting Proceedings 2007; 25: 5048.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr. et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the jnc 7 report. Jama 2003; 289: 2560–72. MEDLINE
e1. Iliopoulos O: Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol 2006; 35: 5593–600.
e2. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W: The von-Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999; 14: 1822–33.
e3. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O: Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2004; 2: 89–95.
e4. Goodman VL, Rock EP, Dagher R et al.: Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 5: 1367–73.
e5. Kane RC, Farrell AT, Saber H et al.: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 24: 7271–8.
e6. Stadler WM: New targets, therapies, and toxicities: lessons to be learned. J Clin Oncol 2006; 1: 4–5.
e7. Tabernero J, Salazar R, Casado E et al.: Targeted therapy in advanced colon cancer: the role of new therapies. Ann Oncol 2004; 15: 55–62.
e8. Johnson DH, Fehrenbacher L, Novotny WF et al.: Randomized phase-II-trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184–91.